FDA issued its first DSCSA Form 483 to a physician-owned practice in 2026
What We Do
Claritas Axis conducts focused, practice-level assessments aligned to current FDA inspection behavior and DSCSA expectations. Our work examines how Rx products are sourced, received, documented, and reconciled within clinical operations. Reviews are scoped to identify exposure, not to implement software or redesign workflows.
Enforcement
The DSCSA, enacted in 2013, was implemented in phases. For nearly a decade, enforcement focused on manufacturers, wholesalers, and national serialization systems. With those controls now in place, regulatory focus has shifted downstream to the final point in the supply chain: the practice itself.
The proof point: In January 2026, the FDA issued its first publicly documented inspection finding against a physician-owned aesthetics practice a med spa in Texas for failures in how injectable drug products were purchased, tracked, and documented. FDA investigators cross-referenced what the practice administered to patients against manufacturer shipment records. The gap was large enough to trigger a formal citation.
These inspections are unannounced, data-driven, and based on real documentation not policy statements. Investigators evaluate whether a practice can prove, with records in hand, that every product it administered came from an authorized, identifiable source.
What FDA Inspectors Now Evaluate
• Purchasing only from federally authorized vendors
• Documentation tying purchased product to administered product
• Alignment between purchase invoices, inventory logs, and treatment records
• Lot number and expiration date traceability
• Written procedures for managing questionable or quarantined product
• A defined, repeatable compliance process backed by written policies
Assessment Areas
What Clients Receive
What Clients Receive
- Authorized trading partner and vendor verification
- Purchase-to-use reconciliation of Rx products
- Product identity, labeling, and documentation controls
- Inspection preparedness and documentation readiness
What Clients Receive
What Clients Receive
What Clients Receive
- A concise summary of identified exposure areas
- Documentation and process gaps tied to inspection risk
- A prioritized remediation roadmap aligned to enforcement expectations
What We Do
Operations & Vendor Readiness Review
Operations & Vendor Readiness Review
Operations & Vendor Readiness Review
Evaluate whether Rx sourcing, vendors, and documentation comply with current enforcement expectations under the Drug Supply Chain Act (DSCSA) to ensure FDA compliance. Additionally, identify any exposure tied to authorized trading partner verification and vendor controls related to RX and pharmaceutical drugs.
Purchase-to-Use Reconciliation
Operations & Vendor Readiness Review
Operations & Vendor Readiness Review
Assess whether the purchased RX and pharmaceutical drugs volumes reconcile to the documented clinical administration, ensuring compliance with the Drug Supply Chain Act (DSCSA). Identify any unexplained variances and record gaps that could pose an inspection risk, maintaining FDA compliance during the medical audit.
Product Identity & Documentation Controls
Product Identity & Documentation Controls
Product Identity & Documentation Controls
Review labeling, lot tracking, storage records, and traceability practices to ensure compliance with the Drug Supply Chain Act (DSCSA) and FDA compliance standards. Additionally, determine whether the physical inventory of RX and pharmaceutical drugs aligns with the documented purchase history during a medical audit.
Inspection Preparedness & Remediation
Product Identity & Documentation Controls
Product Identity & Documentation Controls
Prepare practices for inspection requests, questions, and document production related to FDA compliance, particularly in the context of the Drug Supply Chain Act (DSCSA). Additionally, provide a prioritized remediation roadmap that aligns with FDA inspection behavior, ensuring compliance with regulations affecting RX and pharmaceutical drugs during medical audits.
Copyright © 2026 claritasaxis.com - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.